<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02009982</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00062061</org_study_id>
    <nct_id>NCT02009982</nct_id>
  </id_info>
  <brief_title>Cardioneuroablation for Neurocardiogenic Syncope</brief_title>
  <acronym>Ablate-NCS</acronym>
  <official_title>Cardioneuroablation for Neurocardiogenic Syncope</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David B. De Lurgio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of cardioneuroablation for the&#xD;
      treatment of neurocardiogenic syncope (NCS), also known as &quot;vaso-vagal&quot; syncope. Syncope is a&#xD;
      general term for passing out spells and neurocardiogenic syncope is a specific form of&#xD;
      passing out spells caused by sudden drops in heart rate or blood pressure. Although the&#xD;
      specific mechanisms of NCS are not well understood, it is believed that some people are prone&#xD;
      to developing passing out spells in specific situations such as standing up for a long period&#xD;
      of time, pain or nausea. In these situations, the body reacts with a paradoxical reflex which&#xD;
      leads to a drop in blood pressure and heart rate and causes passing out. Certain types of&#xD;
      medications are used to treat NCS including beta-blockers, midodrine and florinef, among&#xD;
      others. However, none of these medications are particularly effective at preventing passing&#xD;
      out spells and many people continue to have episodes despite trying different medications.&#xD;
&#xD;
      Cardioneuroablation is a new form of treatment for NCS. The term ablation means using a wire&#xD;
      to make small electrical burns in the heart. Ablation has been used for many years to treat&#xD;
      other electrical disturbances in the heart but the use of ablation to treat NCS is a new&#xD;
      application. The goal of cardioneuroablation is to identify areas within the heart which are&#xD;
      believed to initiate the reflex which triggers the drop in heart rate and blood pressure that&#xD;
      leads to passing out. In preliminary studies, it has been suggested that cardioneuroablation&#xD;
      may be significantly more effective than medications at preventing passing out spells for&#xD;
      people with NCS.&#xD;
&#xD;
      Hypothesis: Cardioneuroablation of vagal inputs in the left atrium may serve as an effective&#xD;
      treatment modality for the prevention of NCS by blunting the initial trigger of the cascade&#xD;
      that leads to symptoms and syncope.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Syncope Recurrence Rate</measure>
    <time_frame>12 Months</time_frame>
    <description>The primary endpoint for the study is recurrence of syncope within the 12 month follow-up protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events</measure>
    <time_frame>12 Months</time_frame>
    <description>The secondary endpoint for this study will be the incidence of serious adverse events related to the study procedure within the 12 month follow-up protocol</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Neurocardiogenic Syncope</condition>
  <condition>Vasovagal Syncope</condition>
  <arm_group>
    <arm_group_label>Cardioneuroablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive the cardioneuroablation procedure using the Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Medical Thearpy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in this group will not receive the cardioneuroablation and will continue to be managed using standard medical therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardioneuroablation</intervention_name>
    <description>Catheter Ablation of Vagal Inputs in Left Atrium</description>
    <arm_group_label>Cardioneuroablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter</intervention_name>
    <description>This is the device that will be used to perform the Cardioneuroablation procedure</description>
    <arm_group_label>Cardioneuroablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is able and willing to sign and date the Patient Consent Form&#xD;
&#xD;
          -  Subject is 18 years of age or older&#xD;
&#xD;
          -  Subject is expected to remain available for the follow-up protocol&#xD;
&#xD;
          -  Subject is willing to comply with the follow-up procedures&#xD;
&#xD;
          -  Subject has medically documented history of neurocardiogenic syncope&#xD;
&#xD;
          -  Subject has had 3 episodes of syncope or presyncope in last 12 months&#xD;
&#xD;
          -  Subject has had a positive tilt table test, defined as the presence of syncope or&#xD;
             presyncope associated with abrupt hypotension (SBP &lt; 70 mmHg) or bradycardia (HR &lt; 40&#xD;
             bpm), with or without sublingual nitroglycerin provocation or atropine challenge&#xD;
&#xD;
          -  Subject has been tried on at least one pharmacologic therapy for at least 4 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has signs and symptoms of an active infection (i.e. fever, elevated white&#xD;
             blood cell count, etc.) which has not been treated and/or has not demonstrated&#xD;
             improvement in white blood cell count and resolution of fever&#xD;
&#xD;
          -  Subject is pregnant or planning to become pregnant within the study protocol follow-up&#xD;
&#xD;
          -  Subject is enrolled or planning to participate in a concurrent drug and/or device&#xD;
             study during the course of this study that would confound study results as determined&#xD;
             by the study physician&#xD;
&#xD;
          -  Subject is unwillingly to comply with the randomization procedure&#xD;
&#xD;
          -  Subject has had no syncopal episodes in last six months while on medical therapy&#xD;
&#xD;
          -  Subject has one of the following conditions that is the documented source of syncope:&#xD;
             sick sinus syndrome, sinus node or atrioventricular conduction deficiencies,&#xD;
             ventricular tachyarrhythmias, pulmonary hypertension, hypertrophic cardiomyopathy,&#xD;
             history of transient ischemic attack, seizure disorders, subclavian steal syndrome, or&#xD;
             drug-induced syncope&#xD;
&#xD;
          -  Subjects with a myocardial infarction within last six months&#xD;
&#xD;
          -  Subjects with severe heart failure (NYHA class III or IV), previous heart surgery,&#xD;
             structural heart disease, or an infiltrative cardiac disease&#xD;
&#xD;
          -  Subject is contraindicated for left-atrial ablation, as determined by enrolling&#xD;
             physician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David B DeLurgio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>December 9, 2013</study_first_submitted>
  <study_first_submitted_qc>December 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2013</study_first_posted>
  <results_first_submitted>September 16, 2016</results_first_submitted>
  <results_first_submitted_qc>September 16, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 4, 2016</results_first_posted>
  <last_update_submitted>September 16, 2016</last_update_submitted>
  <last_update_submitted_qc>September 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>David B. De Lurgio</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Fainting</keyword>
  <keyword>Ablation</keyword>
  <keyword>Cardiology</keyword>
  <keyword>Cardiac Electrophysiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syncope</mesh_term>
    <mesh_term>Syncope, Vasovagal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No due to limited data set and study ending.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cardioneuroablation</title>
          <description>Patients in this group received the cardioneuroablation procedure using the Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter&#xD;
Cardioneuroablation: Catheter Ablation of Vagal Inputs in Left Atrium&#xD;
Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter: This is the device that was used to perform the Cardioneuroablation procedure</description>
        </group>
        <group group_id="P2">
          <title>Standard Medical Thearpy</title>
          <description>Patients in this group did not receive the cardioneuroablation and were managed using standard medical therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cardioneuroablation</title>
          <description>Patients in this group received the cardioneuroablation procedure using the Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter&#xD;
Cardioneuroablation: Catheter Ablation of Vagal Inputs in Left Atrium&#xD;
Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter: This is the device that was used to perform the Cardioneuroablation procedure</description>
        </group>
        <group group_id="B2">
          <title>Standard Medical Thearpy</title>
          <description>Patients in this group did not receive the cardioneuroablation and were managed using standard medical therapy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Syncope Recurrence Rate</title>
        <description>The primary endpoint for the study is recurrence of syncope within the 12 month follow-up protocol</description>
        <time_frame>12 Months</time_frame>
        <population>No data was analyzed due to low enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cardioneuroablation</title>
            <description>Patients in this group received the cardioneuroablation procedure using the Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter&#xD;
Cardioneuroablation: Catheter Ablation of Vagal Inputs in Left Atrium&#xD;
Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter: This is the device that was used to perform the Cardioneuroablation procedure</description>
          </group>
          <group group_id="O2">
            <title>Standard Medical Thearpy</title>
            <description>Patients in this group did not receive the cardioneuroablation and were managed using standard medical therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Syncope Recurrence Rate</title>
          <description>The primary endpoint for the study is recurrence of syncope within the 12 month follow-up protocol</description>
          <population>No data was analyzed due to low enrollment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Serious Adverse Events</title>
        <description>The secondary endpoint for this study will be the incidence of serious adverse events related to the study procedure within the 12 month follow-up protocol</description>
        <time_frame>12 Months</time_frame>
        <population>No data was analyzed due to low enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cardioneuroablation</title>
            <description>Patients in this group received the cardioneuroablation procedure using the Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter&#xD;
Cardioneuroablation: Catheter Ablation of Vagal Inputs in Left Atrium&#xD;
Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter: This is the device that was used to perform the Cardioneuroablation procedure</description>
          </group>
          <group group_id="O2">
            <title>Standard Medical Thearpy</title>
            <description>Patients in this group did not receive the cardioneuroablation and were managed using standard medical therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Serious Adverse Events</title>
          <description>The secondary endpoint for this study will be the incidence of serious adverse events related to the study procedure within the 12 month follow-up protocol</description>
          <population>No data was analyzed due to low enrollment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data for adverse events were collected for 12 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cardioneuroablation</title>
          <description>Patients in this group received the cardioneuroablation procedure using the Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter&#xD;
Cardioneuroablation: Catheter Ablation of Vagal Inputs in Left Atrium&#xD;
Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter: This is the device that was used to perform the Cardioneuroablation procedure</description>
        </group>
        <group group_id="E2">
          <title>Standard Medical Thearpy</title>
          <description>Patients in this group did not receive the cardioneuroablation and were managed using standard medical therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tremors</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Shingles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David De Lurgio</name_or_title>
      <organization>Emory University</organization>
      <phone>404-251-1481</phone>
      <email>ddelurg@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

